The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement

The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement

Author Antoneli, Celia Beatriz Gianotti Google Scholar
Ribeiro, Karina Braga Google Scholar
Rodriguez-Galindo, Carlos Google Scholar
Soares, Fernando Augusto Google Scholar
Arias, Victor Eduardo Arrúa Google Scholar
Novaes, Paulo Eduardo Ribeiro dos Santos Google Scholar
Chojniak, Martha Maria Motono Autor UNIFESP Google Scholar
Malogolowkin, Márcio Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Hosp Canc AC Camargo
St Jude Childrens Hosp
Childrens Hosp Los Angeles
Abstract This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/temposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period 1, n = 12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide. vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period 11, n = 18), the treatment consisted of 3 cycles of ifamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and 11 (P = 0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.
Keywords retinoblastoma
extraocular disease
orbital involvement
survival
chemotherapy
Language English
Date 2007-10-01
Published in Journal Of Pediatric Hematology Oncology. Philadelphia: Lippincott Williams & Wilkins, v. 29, n. 10, p. 700-704, 2007.
ISSN 1077-4114 (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 700-704
Origin http://dx.doi.org/10.1097/MPH.0b013e31814fb7ea
Access rights Closed access
Type Article
Web of Science ID WOS:000250453100005
URI http://repositorio.unifesp.br/11600/44548

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account